Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in the interest of Mr. D J Phelan in Ordinary Share ADRs. This change resulted from the re-investment of a dividend paid to shareholders on July 9, 2009. The transaction occurred at a price of $35.72 per ADR, resulting in a holding of 201.70 ADRs.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific insider transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 14, 2009 (Notification date); July 9, 2009 (Dividend payment date).
- Individual Involved: Mr. D J Phelan.
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Price per ADR: $35.72.
- Resulting Holding: 201.70 ADRs.